AI assistant
UroGen Pharma Ltd. — Director's Dealing 2019
Jan 15, 2019
32312_dirs_2019-01-15_dafb92d0-45a1-46e9-bb74-8671f1bbb0de.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3/A — Form 3/A
Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2019-01-01
Reporting Person: Cohen Fred E (Director)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $16.99 | 2027-05-15 | Ordinary Shares (40000) | Direct | |
| Stock Option (right to buy) | $59.23 | 2028-06-04 | Ordinary Shares (10000) | Direct |
Footnotes
F1: 6.25% of the shares underlying the stock option vested on each of August 15, 2017, November 15, 2017 and February 15, 2018; 31.25% of the shares vested May 15, 2018 and the remaining shares will vest in equal quarterly installment commencing 3 months after May 15, 2018.
F2: The information in column 3 and column 4 were inadvertently transposed on the initial Form 3 filing.
F3: 25% of the shares underlying the stock option vested on each of September 4, 2018 and December 4, 2018 and the remaining shares will in two equal installments on March 4, 2019 and June 4, 2019.